Company / Cost of Revenue
PULSE BIOSCIENCES, INC. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$539.0K
FY2025
5-year range
$0 / $11.9M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#112 of 113
Health Care
What the data says
Among 113 Health Care companies, PULSE BIOSCIENCES, INC. is in the top 1% for cost of revenue. Cost of Revenue has fluctuated over the past 10 years, ranging from $0 in FY2024 to $12M in FY2023.
Based on SEC 10-K filings.
$539,000 in FY2025 with a 3-year CAGR of -64.4%.
Improved from $12M to $539,000 over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -64.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 113This company $539.0K Sector average $11.3B
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -64.4%, indicating a declining trend.
- Ranks #112 out of 113 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
- Lowest cost of revenue in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $539.0K | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $11.9M | +0.0% |
| FY2022 | $11.9M | +1890.7% |
| FY2021 | $600.0K | - |
| FY2020 | $0 | -100.0% |
| FY2019 | $600.0K | +0.0% |
| FY2018 | $600.0K | -25.0% |
| FY2017 | $800.0K | +60.0% |
| FY2016 | $500.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026